Diebold Nixdorf, Incorporated
DBDTechnologyNASDAQSoftware - Application
Scan Results
Daily timeframeDiebold Nixdorf, Incorporated engages in the automating, digitizing, and transforming the way people bank and shop worldwide. The company carries a $2.33B market cap, placing it firmly in the mid-cap category. It operates through two segments, Banking and Retail.
Market Cap
$2.33B
Beta
1.14
P/E (TTM)
22.74
P/E (Fwd)
9.78
EPS (TTM)
$3.02
EPS (Fwd)
$7.02
ROE
10.9%
ROA
5.8%
Cash
$267.2M
Total Debt
$1.11B
Free CF
$312.0M
52W Change
12.8%
Annual Financials
Cash vs Debt
Where DBD stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, DBD finished 14.70% below its 150-day moving average ($78.14) and 11.48% below its 200-day moving average ($75.29). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is DBD overbought or oversold?
At the September 2, 2026 close, DBD's RSI(14) was 31.3, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $267.2M in cash, though total debt stands at $1.11B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company generates $312.0M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 10.9%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 5.8% suggests reasonable efficiency in deploying the company's asset base. Revenue has been relatively flat, moving from $3.91B (2021) to $3.81B (2025).
As with any equity investment, DBD carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing DBD.